Press Releases

Shuttle Pharma Awarded a New Patent for Selective Inhibitors for Cancer Treatment

Jul 29, 2021

ROCKVILLE, Md., July 29, 2021 — Shuttle Pharmaceuticals Holdings, Inc (Shuttle Pharma), a Maryland-based developer of new drugs for cancer treatment, was awarded US Patent No.: 11,034,667 B2 for “Selective Histone Deacetylase Inhibitors for the treatment of Human Disease.” These non-cytotoxic, highly selective inhibitors target the histone deacetylase 6 (HDAC6) enzyme to stimulate the immune system for applications in the treatment of cancers, neurological diseases and immunological disorders.

Lead inventor Scott Grindrod, PhD describes histone deacetylase (HDAC) inhibitors as “a novel class of drugs that target enzymes involved in regulation of critical cellular functions that can inhibit cancer growth and activate cellular immunity. These are key target functions to improve cancer treatment. HDAC6 regulates the innate immune system and will be tested to activate an anti-cancer immune response to increase the effectiveness of chemotherapy and radiation therapy. The molecules in this patent enhance Shuttle Pharma's platform technology of selective inhibitor discovery for cancer treatment.”

About Shuttle Pharmaceuticals, Inc.

Shuttle Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company leveraging proprietary technology to develop novel therapies designed to cure cancers. The company is a pioneer in distinct areas related to the treatment of cancers in combinations with radiation therapy and holds other HDAC inhibitor patents that confer cancer radiation sensitization and normal tissue protection. Shuttle's HDAC6 selective inhibitors polarize macrophages to an anti-cancer state to stimulate the innate immune response for cancer treatment.

Forward looking statement

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (I) change without notice, (ii) factors beyond the Company's control and (iii) the financial capabilities of the Company. Forward looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For more information about Shuttle, please visit

Skip to content